摘要
目的 :检测原发性乳腺癌常规病理检查阴性淋巴结和骨髓中微转移的发生及与其它临床参考指标的关系。方法 :利用逆转录 聚合酶链反应 (RT PCR)方法联合检测腋窝淋巴结和骨髓中细胞角蛋白 19(CK 19)基因表达。将乳腺癌细胞株 (T47D)与骨髓细胞按不同比例混合 ,比较RT PCR与免疫组化 (IHC)方法的检测敏感性。结果 :35例乳腺癌共 137枚淋巴结有 8例 11枚CK 19表达阳性 ;35份骨髓标本 ,其中 8份CK 19表达阳性。淋巴结或骨髓阳性表达共 14例 (4 0 % )。RT PCR方法能检出 1∶5× 10 5肿瘤细胞 ,而IHC方法仅能检出 1∶5× 10 4 。微转移与其它临床指标未见明显相关性。结论 :以CK 19为标志物 ,RT PCR方法检测原发性乳腺癌微转移灵敏、特异 。
Objective:To detect micrometastases of axillary lymph modes and bone marrow in breast cancer patients with negative lymph nodes by routine pathologic examination and compared with other clinical Parameters.Methods:mRNA of cytokeratin 19 gene expression was determined by reverse transcriptase polymerase chain reaction (RT PCR).Human breast cancer cell line T47D was mixed with bone marrow cells at different proportions.The positive detection rate was compared between RT PCR and immunohistochemistry (IHC) methods.Results:Positive expression of CK 19 was observed in 11 lymph nodes of 8 cases by RT PCR detection.Total positive cases including axillary lymph nodes and bone marrow were 14(40%).CK 19 positive cells were detected by RT PCR at the proportion of 1:5×10 5,while only 1:5×10 4 was detected by IHC method.There was no correlation found between CK 19 method and other clinical parameters.Conclusion:Detection of micrometastases of axillary lymph nodes and bone marrow by using CK 19 as biological marker is sensitive and specific for primary breast cancer,and it can be a predict of prognosis for clinical treatment.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2000年第8期571-574,共4页
Chinese Journal of Clinical Oncology
基金
北京市乳腺癌重点学科发展基金资助
